Patients with idiopathicachalasia show a significant difference in the distribution of SNPs affecting VIPR1.[11]
VIP and PACAP levels were decreased in anterior vaginal wall of stress urinary incontinence and pelvic organ prolapse patients, they may participate in the pathophysiology of these diseases.[12]
^Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S (Apr 1992). "Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide". Neuron. 8 (4): 811–9. doi:10.1016/0896-6273(92)90101-I. PMID1314625. S2CID43589458.
^Usdin TB, Bonner TI, Mezey E (Dec 1994). "Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions". Endocrinology. 135 (6): 2662–80. doi:10.1210/endo.135.6.7988457. PMID7988457.
^Nam C, Case AJ, Hostager BS, O'Dorisio MS (Feb 2009). "The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation". Journal of Molecular Neuroscience. 37 (2): 160–7. doi:10.1007/s12031-008-9119-x. PMID18663606. S2CID2030939.
^Freson K, Peeters K, De Vos R, Wittevrongel C, Thys C, Hoylaerts MF, Vermylen J, Van Geet C (Feb 2008). "PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications". Blood. 111 (4): 1885–93. doi:10.1182/blood-2007-06-098558. PMID18000164. S2CID24342247.
^Paladini F, Cocco E, Cascino I, Belfiore F, Badiali D, Piretta L, Alghisi F, Anzini F, Fiorillo MT, Corazziari E, Sorrentino R (Jun 2009). "Age-dependent association of idiopathic achalasia with vasoactive intestinal peptide receptor 1 gene". Neurogastroenterology and Motility. 21 (6): 597–602. doi:10.1111/j.1365-2982.2009.01284.x. PMID19309439. S2CID24081228.
^Hong X, Huang L, Song Y (Aug 2008). "Role of vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide in the vaginal wall of women with stress urinary incontinence and pelvic organ prolapse". International Urogynecology Journal and Pelvic Floor Dysfunction. 19 (8): 1151–7. doi:10.1007/s00192-008-0585-z. PMID18351280. S2CID2482642.
Further reading
"[Quaternary structure of rabbit skeletal muscle glycogen synthetase]" [Quaternary structure of rabbit skeletal muscle glycogen synthetase]. Doklady Akademii Nauk SSSR. 222 (4): 997–1000. Jun 1975. PMID807467.
Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P, Laburthe M (Jan 1995). "Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP". Biochemical and Biophysical Research Communications. 206 (1): 246–52. doi:10.1006/bbrc.1995.1034. PMID7818527.
Gagnon AW, Aiyar N, Elshourbagy NA (Mar 1994). "Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor". Cellular Signalling. 6 (3): 321–33. doi:10.1016/0898-6568(94)90037-X. PMID7917790.
Sreedharan SP, Patel DR, Xia M, Ichikawa S, Goetzl EJ (Aug 1994). "Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways". Biochemical and Biophysical Research Communications. 203 (1): 141–8. doi:10.1006/bbrc.1994.2160. PMID8074647.
Couvineau A, Rouyer-Fessard C, Darmoul D, Maoret JJ, Carrero I, Ogier-Denis E, Laburthe M (Apr 1994). "Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains". Biochemical and Biophysical Research Communications. 200 (2): 769–76. doi:10.1006/bbrc.1994.1517. PMID8179610.
Sreedharan SP, Patel DR, Huang JX, Goetzl EJ (Jun 1993). "Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor". Biochemical and Biophysical Research Communications. 193 (2): 546–53. doi:10.1006/bbrc.1993.1658. PMID8390245.
Couvineau A, Fabre C, Gaudin P, Maoret JJ, Laburthe M (Feb 1996). "Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane". Biochemistry. 35 (6): 1745–52. doi:10.1021/bi952022h. PMID8639654.
Pozo D, Guerrero JM, Segura JJ, Calvo JR (Sep 1996). "Thymosin alpha 1 interacts with the VIP receptor-effector system in rat and mouse immunocompetent cells". Immunopharmacology. 34 (2–3): 113–23. doi:10.1016/0162-3109(96)00131-2. PMID8886855.
Knudsen SM, Tams JW, Wulff BS, Fahrenkrug J (Dec 1998). "Importance of conserved cysteines in the extracellular loops of human PACAP/VIP1 receptor for ligand binding and stimulation of cAMP production". Annals of the New York Academy of Sciences. 865 (1): 259–65. Bibcode:1998NYASA.865..259K. doi:10.1111/j.1749-6632.1998.tb11186.x. PMID9928020. S2CID27000806.
Nicole P, Maoret JJ, Couvineau A, Momany FA, Laburthe M (Sep 2000). "Tryptophan 67 in the human VPAC(1) receptor: crucial role for VIP binding". Biochemical and Biophysical Research Communications. 276 (2): 654–9. doi:10.1006/bbrc.2000.3375. PMID11027527.
Bajo AM, Juarranz MG, Valenzuela P, Martínez P, Prieto JC, Guijarro LG (Sep 2000). "Expression of vasoactive intestinal peptide (VIP) receptors in human uterus". Peptides. 21 (9): 1383–8. doi:10.1016/S0196-9781(00)00282-5. PMID11072126. S2CID429907.
Martin Shreeve S (Feb 2002). "Identification of G-proteins coupling to the vasoactive intestinal peptide receptor VPAC(1) using immunoaffinity chromatography: evidence for precoupling". Biochemical and Biophysical Research Communications. 290 (4): 1300–7. doi:10.1006/bbrc.2002.6342. PMID11812005.